Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$38.20 USD
-0.95 (-2.43%)
Updated Sep 29, 2023 04:00 PM ET
After-Market: $38.21 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HALO 38.20 -0.95(-2.43%)
Will HALO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HALO
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Halozyme Therapeutics (HALO) Down 3.8% Since Last Earnings Report: Can It Rebound?
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Other News for HALO
First Week of HALO October 20th Options Trading
7 Sleeper Stocks That Should Be on Every Investor’s Radar This Fall
Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 10,000 Shares of Halozyme ...
Halozyme: Intriguing Buy Prospect Despite This Week's PDUFA Setback
Berenberg Bank Sticks to Its Buy Rating for Halozyme (HALO)